News

RBC Capital names top healthcare stocks as sector upgraded to overweight

Investing.com -- RBC Capital has upgraded the Healthcare sector to Overweight from Market Weight, identifying 11 high-conviction stock ideas across therapeutics and non-therapeutics segments. The upgrade is supported by improving flows, positive earnings and sales revision profiles, and attractive valuations. RBC Head of Equity Strategy Lori Calvasina noted that Healthcare historically moves inversely to Technology’s relative performance versus the S&P 500, making it a natural destination when r

Yahoo·15:27

ASND Shares Shrug Off Positive European Opinion For FDA-Approved Achondroplasia Drug

Ascendis said the Committee for Medicinal Products for Human Use adopted a positive opinion on Ascendis’s application seeking approval for the drug in achondroplasia.

Yahoo·16:30ASND

Ascendis Pharma's TransCon CNP Gets Positive EU Recommendation for Children With Achondroplasia

Ascendis Pharma (ASND) said Friday that the European Medicines Agency's Committee for Medicinal Prod

Yahoo·08:58ASND

Once-Weekly TransCon® CNP (Navepegritide) Receives Positive CHMP Opinion for the Treatment of Achondroplasia in Children

Final European Commission decision expected during Q4 2026COPENHAGEN, Denmark, Oct. 16, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization for once-weekly TransCon CNP (navepegritide) in the European Union for the treatment of achondroplasia in children two years of age and older whose epiphyses are not

Yahoo·08:29ASND

Ascendis Pharma Receives Positive Opinion From Committee For Medicinal Products For Human Use Of European Medicines Agency For Marketing Authorization Of TransCon CNP In EU To Treat Achondroplasia

Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending marketing authorization

Benzinga·04:31ASND

Liberty All-Star® Growth Fund, Inc. September 2026 Monthly Update

BOSTON, October 14, 2026--Liberty All-Star® Growth Fund, Inc. September 2026 Monthly Update

Yahoo·13:50

Here’s How Much You Would Have Made Owning Ascendis Pharma Stock In The Last 10 Years

Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 13.7% on an annualized basis producing an average annual return of 27.5%. Currently, Ascendis Pharma has a market capitalization of

Benzinga·07:30ASND

FDA Grants Priority Review to BridgeBio's Dwarfism Drug Filing

BBIO wins FDA priority review for infigratinib, potentially making it the first approved oral therapy for achondroplasia.

Yahoo·10:37

Ascendis to Share Latest Advances in Hypoparathyroidism and Achondroplasia Programs at ASBMR 2026

COPENHAGEN, Denmark, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (Nasdaq: ASND) today announced that the latest advances in its hypoparathyroidism and achondroplasia programs will be showcased during ASBMR 2026, the annual meeting of American Society for Bone & Mineral Research being held in Boston from October 9-12, 2026. Updates include an oral presentation by Aliya Khan, M.D., of combined skeletal data from the Phase 2 PaTH Forward and Phase 3 PaTHway trials showing normalization of

Yahoo·09:15ASND

This Biotech’s Proprietary Platform Could Unlock Its Next Growth Phase

Baird Equity Asset Management recently released its “Small/Mid Cap Growth Strategy” second-quarter 2026 investor letter. A copy of the letter can be downloaded here. The fund benefited from a sharp rebound in the broader equity market during the second quarter of 2026, as improving corporate earnings, resilient economic growth, moderating inflation, and continued artificial intelligence […]

Yahoo·09:47

Here's How Much $1000 Invested In Ascendis Pharma 10 Years Ago Would Be Worth Today

Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 10 years by 14.04% on an annualized basis producing an average annual return of 27.55%. Currently, Ascendis Pharma has a market capitalization of

Benzinga·13:45ASND

BioMarin Pharmaceutical Inks License Deal With Ascendis Pharma; Grants Ascendis License For Transcon Cnp, Navepegritide, Yuviwel; Ascendis To Pay Biomarin 20% U.S., 18% EU/Br/Sk Royalty On Sales Until May 2030; All Pending Litigation Dismissed

https://www.sec.gov/ix?doc=/Archives/edgar/data/1048477/000162828026063981/bmrn-20260924.htm

Benzinga·12:22ASND

Novo Nordisk: Capital Markets Day Reveals Its Next Growth Engine

Novo Nordisk A/S’s 2030 pipeline targets, Wegovy pill growth and Q2 sales show major upside. Click for this NVO stock update.

SeekingAlpha·05:39

Ascendis Pharma (ASND) Authorizes $400M Share Buyback

On September 14, Ascendis Pharma A/S (NASDAQ:ASND) said its Board had authorized buying back up to $400 million of its own ordinary shares. That is a striking move from a company that lost money in the second quarter of 2025. Here is what stands behind the announcement, and what the fine print does and does […]

Yahoo·22:55ASND

Ascendis Pharma (ASND) Regains Exclusive Rights To Key TransCon Metabolic Programs

Ascendis Pharma (NasdaqGS:ASND) has regained exclusive rights to TransCon technology-based products in metabolic and cardiovascular diseases after ending its collaboration with Novo Nordisk. The company plans to advance its own programs in obesity and type 2 diabetes using its TransCon platform. Management highlighted once-monthly TransCon Semaglutide as a planned program within its expanded metabolic disease pipeline. The regained TransCon metabolic and cardiovascular rights and plans for...

Yahoo·06:09ASND

Ascendis Pharma (ASND) Will Regain Metabolic Drug Rights. Is Greater Ownership Worth the Cost?

Ascendis Pharma A/S (NASDAQ:ASND) announced on September 14 that it will regain exclusive rights to develop, manufacture, and commercialize TransCon products in metabolic and cardiovascular diseases following the termination of its collaboration with Novo Nordisk A/S (NYSE:NVO). The rights include once-monthly TransCon Semaglutide, an investigational long-acting prodrug of semaglutide intended for obesity and type 2 […]

Yahoo·16:55ASND

BioMarin Stops Voxzogo Development for Noonan Syndrome

BMRN ends Voxzogo development for Noonan syndrome as the drug faces new competition and pursues other growth opportunities.

Yahoo·12:01

Ascendis Pharma: Back To Full Independence

Ascendis Pharma faces negative sentiment after Novo returned TransCon rights, compounding prior partner exits and disappointments. Read more on ASND stock here.

SeekingAlpha·11:02ASND

Ascendis Has Capacity To Execute Alone After Termination of Novo Nordisk Collaboration, Wedbush Says

Ascendis Pharma (ASND) share selloff on Tuesday after the termination of its collaboration agreement

Yahoo·10:46ASND

Ascendis Pharma A/S (ASND) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Ascendis Pharma A/S (ASND) Morgan Stanley 24th Annual Global Healthcare Conference September 15, 2026 8:30 AM EDTCompany ParticipantsJan Mikkelsen -...

SeekingAlpha·14:01ASND

Why Is Ascendis Pharma Stock Trading Lower on Tuesday?

Ascendis Pharma shares dip as it reclaims TransCon technology rights from Novo Nordisk and initiates a $400 million share repurchase program.

Benzinga·09:56ASND

Raymond James Downgrades Ascendis Pharma to Outperform, Maintains Price Target to $287

Raymond James analyst Martin Auster downgrades Ascendis Pharma (NASDAQ:ASND) from Strong Buy to Outperform and maintains the price target from $287 to $287.

Benzinga·05:52ASND

Oppenheimer Maintains Outperform on Ascendis Pharma, Raises Price Target to $312

Oppenheimer analyst Leland Gershell maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $304 to $312.

Benzinga·08:55ASND

Morgan Stanley Maintains Overweight on Ascendis Pharma, Lowers Price Target to $273

Morgan Stanley analyst Maxwell Skor maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $275 to $273.

Benzinga·08:11ASND

Ascendis Pharma (NASDAQ:ASND) Passes Minervini Trend Template and High Growth Momentum Screen

Passes Minervini Trend Template & High Growth Momentum: Ascendis Pharma (ASND) shows strong uptrend, accelerating growth, and analyst upgrades.

ChartMill·04:50ASND

Wedbush Reiterates Outperform on Ascendis Pharma, Maintains $327 Price Target

Wedbush analyst Yun Zhong reiterates Ascendis Pharma (NASDAQ:ASND) with a Outperform and maintains $327 price target.

B of A Securities Maintains Buy on Ascendis Pharma, Lowers Price Target to $304

B of A Securities analyst Tazeen Ahmad maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $306 to $304.

Benzinga·09:45ASND

Jefferies Maintains Buy on Ascendis Pharma, Lowers Price Target to $330

Jefferies analyst Kelly Shi maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $333 to $330.

Benzinga·09:31ASND

Stifel Maintains Buy on Ascendis Pharma, Lowers Price Target to $326

Stifel analyst Alex Thompson maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and lowers the price target from $328 to $326.

BMO Capital Initiates Coverage On Ascendis Pharma with Outperform Rating, Announces Price Target of $319

BMO Capital analyst David Lebowitz initiates coverage on Ascendis Pharma (NASDAQ:ASND) with a Outperform rating and announces Price Target of $319.

Benzinga·02:07ASND

TD Cowen Maintains Buy on Ascendis Pharma, Raises Price Target to $341

TD Cowen analyst Yaron Werber maintains Ascendis Pharma (NASDAQ:ASND) with a Buy and raises the price target from $325 to $341.

Benzinga·08:00ASND

RBC Capital Maintains Outperform on Ascendis Pharma, Raises Price Target to $290

RBC Capital analyst Luca Issi maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $280 to $290.

Benzinga·07:25ASND

Barclays Maintains Overweight on Ascendis Pharma, Lowers Price Target to $329

Barclays analyst Eliana Merle maintains Ascendis Pharma (NASDAQ:ASND) with a Overweight and lowers the price target from $345 to $329.

Benzinga·06:18ASND

Ascendis Pharma A/S (ASND) Q2 2026 Earnings Call Transcript

Ascendis Pharma A/S (ASND) Q2 2026 Earnings Call August 13, 2026 8:00 AM EDTCompany ParticipantsChad Fugure - Vice President of Investor RelationsJan...

SeekingAlpha·10:57ASND

Full Transcript: Ascendis Pharma Q2 2026 Earnings Call

Ascendis Pharma (NASDAQ:ASND) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. Benzinga APIs provide real-time access to

Benzinga·05:26ASND

Ascendis Pharma Q2 Adj. EPS $1.05 Beats $0.78 Estimate, Sales $394.437M Beat $353.800M Estimate

Ascendis Pharma (NASDAQ:ASND) reported quarterly earnings of $1.05 per share which beat the analyst consensus estimate of $0.78 by 34.62 percent. This is a 212.9 percent increase over losses of $(0.93) per share from

Benzinga·03:31ASND

Ascendis Pharma (NASDAQ:ASND) Combines High Growth Momentum with a Breakout Setup

Ascendis Pharma (ASND) shows high growth momentum with a technical setup rating of 8, triple-digit sales growth, and strong analyst revisions.

ChartMill·06:41ASND

Here's How Much $100 Invested In Ascendis Pharma 5 Years Ago Would Be Worth Today

Ascendis Pharma (NASDAQ:ASND) has outperformed the market over the past 5 years by 5.62% on an annualized basis producing an average annual return of 17.21%. Currently, Ascendis Pharma has a market capitalization of

Benzinga·06:15ASND